Increased Risk of Breast Cancer Death Linked to Missed Screening Appointments

A recent study reveals that women who miss their initial breast cancer screening appointment face a 40% greater risk of dying from the disease. This research, conducted by experts at the Karolinska Institute in Sweden, analyzed data from approximately half a million women across the country. The findings were published in the British Medical Journal. The participants were invited for their first screening between 1991 and 2020, and their health was monitored for as long as 25 years.

After considering various factors, including social and economic conditions, about 32% of the women did not attend their first mammogram. The research uncovered a significant connection between skipping the first screening and an increased risk of breast cancer mortality—9.9 deaths per 1,000 women over 25 years, compared to seven deaths per 1,000 among those who were screened.

Additionally, those who missed their first appointment were also less inclined to participate in future screenings and were more likely to receive a diagnosis of advanced breast cancer. Interestingly, the overall breast cancer rate over the 25 years was similar between both groups. This indicates that the higher death rates among non-attendees are likely due to delayed detection rather than a higher incidence of the disease, according to the research team.

The researchers noted that women who did not attend their first screening had a 40% greater risk of mortality from breast cancer over the long term. They mentioned, “If early screening behavior is predictive of later-stage diagnosis and mortality risk, it could offer a critical chance to identify at-risk populations long before adverse outcomes arise.”

In a related editorial, US researchers commented that attending the first appointment goes beyond just a brief health check. Most women probably won’t be diagnosed with cancer at that initial visit, but simply attending could provide valuable information on reducing risks and recognizing symptoms, contributing to long-term breast health and survival.

Globally, breast screening eligibility varies. For instance, in England, women are invited for breast screening between the ages of 50 and 71, and ideally should receive their first mammogram invitation by age 53. According to the latest data from the NHS, around 70% of eligible women were up to date with screenings as of March 2024, indicating that nearly one in three were not.

Claire Rowney, CEO of Breast Cancer Now, expressed concern about the high number of women who missed their first appointment and emphasized the need for urgent measures to ensure that all women are encouraged and able to get screened.

In related news, separate research predicts that the global cancer death toll may rise by nearly 75% to 18.6 million by 2050. New cases are expected to increase by 61% in the coming 25 years, with the increase largely attributed to population growth and an aging demographic. However, it was noted that 42% of cancer deaths are linked to modifiable risk factors, such as smoking and unhealthy diets.

On a more hopeful note, researchers recently identified a potential target for drug treatments that could halt pancreatic cancer in its tracks. Their studies focused on pancreatic ductal adenocarcinoma (PDAC), the most common and aggressive form of the disease. They discovered that blocking a protein called SPP1 could prevent cancer spread and enhance survival. These findings, published in the journal Nature, could pave the way for new medications aimed at this protein.

Professor Axel Behrens from the Institute of Cancer Research in London mentioned that this could lead to a drug specifically designed to target the protein, potentially allowing for better patient outcomes.